Johnson & Johnson $JNJ Shares Sold by Berry Wealth Group LP

Berry Wealth Group LP lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 88.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,094 shares of the company’s stock after selling 16,242 shares during the quarter. Johnson & Johnson comprises 1.3% of Berry Wealth Group LP’s portfolio, making the stock its 19th largest position. Berry Wealth Group LP’s holdings in Johnson & Johnson were worth $388,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $26,000. Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth about $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. Finally, Compass Financial Services Inc lifted its position in Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last ninety days. Insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for TECVAYLI® (teclistamab) in combination with DARZALEX FASPRO® for relapsed/refractory multiple myeloma expands J&J’s label into earlier lines of therapy, with Phase 3 data showing significant progression‑free and overall survival benefits — a potential new standard of care and meaningful long‑term revenue upside for the oncology portfolio. PR Newswire: TECVAYLI + DARZALEX approval Reuters: FDA approves JNJ blood cancer drug
• Neutral Sentiment: JPMorgan raised its price target to $250 but kept a “neutral” rating — the higher target signals upside potential acknowledged by analysts, yet the maintained rating tempers immediate buy-side enthusiasm. Benzinga / TickerReport: JPMorgan price target
• Neutral Sentiment: J&J launched a direct‑to‑consumer website to sell certain drugs to uninsured or out‑of‑pocket U.S. patients — a strategic move to improve access and potentially capture incremental retail revenue, though initial impact on top line is uncertain. Reuters: direct-to-consumer site
• Neutral Sentiment: Pipeline progress: J&J is advancing nipocalimab (Fast Track for SLE) with Phase 3 underway — positive R&D momentum that supports future growth, offset by competing legal/claim disputes noted in coverage. Yahoo Finance: nipocalimab progress & legal challenge
• Negative Sentiment: Two J&J units agreed to pay $65 million to settle a Tracleer antitrust class action alleging overcharges — a direct legal expense and reminder of ongoing litigation risks, though the amount is modest versus J&J’s market cap. Reuters: $65M Tracleer settlement
• Negative Sentiment: Market reaction: coverage notes J&J shares declined more than the broader market during the session, reflecting that investors are weighing legal/settlement headlines and profit‑taking despite the positive FDA news. Zacks: JNJ declines more than market

Johnson & Johnson Stock Down 2.3%

Shares of JNJ stock opened at $239.65 on Friday. The stock has a 50 day moving average of $227.70 and a 200-day moving average of $203.56. The firm has a market cap of $577.53 billion, a PE ratio of 21.69, a price-to-earnings-growth ratio of 2.42 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s payout ratio is 47.06%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Wolfe Research raised their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Guggenheim upped their price target on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a report on Friday, January 23rd. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $234.87.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.